# Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

> **NCT00143312** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 45 (actual)

## Conditions studied

- Prophylaxis Of Invasive Fungal Infections

## Interventions

- **DRUG:** voriconazole

## Key facts

- **NCT ID:** NCT00143312
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2009-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143312, "Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00143312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*